Adam Crystal Sells 12,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $20.11, for a total value of $241,320.00. Following the completion of the transaction, the insider directly owned 112,622 shares of the company’s stock, valued at approximately $2,264,828.42. This trade represents a 9.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Adam Crystal also recently made the following trade(s):

• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00.
• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total transaction of $226,221.52.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $19.26 on Friday. Tango Therapeutics, Inc. has a twelve month low of $1.03 and a twelve month high of $21.82. The firm has a market cap of $2.75 billion, a P/E ratio of -22.14 and a beta of 1.76. The firm’s 50-day simple moving average is $14.29 and its 200-day simple moving average is $10.66.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, equities analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TNGX has been the topic of several research analyst reports. Wall Street Zen cut shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Piper Sandler lifted their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Mizuho boosted their target price on Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, March 11th. Guggenheim increased their price target on Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $18.00 price target on shares of Tango Therapeutics in a report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Hedge Funds Weigh In On Tango Therapeutics

Large investors have recently made changes to their positions in the company. Farallon Capital Management LLC boosted its holdings in Tango Therapeutics by 21.4% in the fourth quarter. Farallon Capital Management LLC now owns 13,061,411 shares of the company’s stock valued at $115,724,000 after acquiring an additional 2,304,411 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Tango Therapeutics by 322.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after purchasing an additional 8,096,924 shares during the last quarter. Siren L.L.C. lifted its position in Tango Therapeutics by 38.8% during the 4th quarter. Siren L.L.C. now owns 8,165,374 shares of the company’s stock valued at $72,345,000 after purchasing an additional 2,282,186 shares during the period. Vanguard Group Inc. lifted its position in Tango Therapeutics by 33.6% during the 4th quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock valued at $59,814,000 after purchasing an additional 1,698,974 shares during the period. Finally, State Street Corp boosted its stake in shares of Tango Therapeutics by 84.8% in the 4th quarter. State Street Corp now owns 6,218,567 shares of the company’s stock valued at $55,097,000 after purchasing an additional 2,853,362 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.